Informações:
Falhas:
ID
34325
Descrição
Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C; ODM derived from: https://clinicaltrials.gov/show/NCT01754974
Link
https://clinicaltrials.gov/show/NCT01754974
Palavras-chave
Versões (1)
- 16/01/2019 16/01/2019 -
Titular dos direitos
see on clinicaltrials.gov
Transferido a
16 de janeiro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Hepatitis C Virus (HCV) NCT01754974
Eligibility Hepatitis C Virus (HCV) NCT01754974
- StudyEvent: Eligibility
Similar models
Eligibility Hepatitis C Virus (HCV) NCT01754974
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
ID.1
Item
chronic hepatitis c, genotype 1
boolean
ID.2
Item
hcv rna ≥100,000 iu/ml at screening
boolean
ID.3
Item
liver biopsy documenting no cirrhosis (within prior 3 years). where approved for staging of liver disease, non-invasive imaging may be used to assess the extent of liver disease
boolean
ID.4
Item
naïve to prior anti-hcv therapy
boolean
ID.5
Item
infected with hcv other than genotype 1
boolean
ID.6
Item
positive hepatitis b surface antigen (hbsag), or human immunodeficiency virus (hiv)-1/hiv-2 antibody at screening
boolean
ID.7
Item
evidence of liver disease other than hcv
boolean
ID.8
Item
active substance abuse
boolean
ID.9
Item
use of hematologic growth factors within 90 days prior to study randomization
boolean
ID.10
Item
evidence of history of cirrhosis based on radiologic criteria or biopsy results and clinical criteria
boolean